Literature DB >> 15265511

Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted.

Hiroyuki Yamanaka1, Miki Nakajima, Kiyoko Nishimura, Ryoko Yoshida, Tatsuki Fukami, Miki Katoh, Tsuyoshi Yokoi.   

Abstract

Generally, 70-80% of absorbed nicotine is mainly metabolized to cotinine by cytochrome P450 (CYP) 2A6. There is genetic polymorphism in the human CYP2A6 gene. Among several mutated alleles, CYP2A6*4 allele is a whole deleted type. The purpose of the present study was to clarify the metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for nicotine and its nine metabolites. Excretion levels of nicotine and its metabolites in 24 h accumulated urine after the chewing of one piece of nicotine gum were evaluated in five Japanese subjects whose CYP2A6 genotype was determined. In three subjects with CYP2A6*1A/CYP2A6*1A, CYP2A6*1A/CYP2A6*1B, and CYP2A6*1A/CYP2A6*4 (group I), nicotine was mainly excreted as cotinine, trans-3'-hydroxycotinine, and their glucuronide (approximately 60%). In contrast, in two subjects with CYP2A6*4/CYP2A6*4 (group II), trace levels of cotinine, cotinine N-glucuronide, and cotinine 1'-N-oxide were detected. Trans-3'-hydroxycotinine and its O-glucuronide were not detected. The excretion levels of nicotine itself, nicotine N-glucuronide, and nicotine 1'-N-oxide were higher than those in the other three subjects. The total excretion levels of these three compounds were approximately 95% in group II versus 35% in group I. However, the sum of the excretion levels of nicotine and all metabolites was similar among these five subjects. This is the first report of the metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265511     DOI: 10.1016/j.ejps.2004.04.012

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  27 in total

1.  UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.

Authors:  Jeannette Zinggeler Berg; Linda B von Weymarn; Elizabeth A Thompson; Katherine M Wickham; Natalie A Weisensel; Dorothy K Hatsukami; Sharon E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

2.  A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine.

Authors:  Taraneh Taghavi; Maria Novalen; Caryn Lerman; Tony P George; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-31       Impact factor: 4.254

3.  Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.

Authors:  Sharon E Murphy
Journal:  Chem Res Toxicol       Date:  2016-11-22       Impact factor: 3.739

4.  Characterization of CYP2B6 in a CYP2B6-humanized mouse model: inducibility in the liver by phenobarbital and dexamethasone and role in nicotine metabolism in vivo.

Authors:  Zhihua Liu; Lei Li; Hong Wu; Jing Hu; Jun Ma; Qing-Yu Zhang; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2014-11-19       Impact factor: 3.922

5.  The Role of Genetics in Nicotine Dependence: Mapping the Pathways from Genome to Syndrome.

Authors:  James Mackillop; Ezemenari Obasi; Michael T Amlung; John E McGeary; Valerie S Knopik
Journal:  Curr Cardiovasc Risk Rep       Date:  2010-11

6.  Nicotine exposure and metabolizer phenotypes from analysis of urinary nicotine and its 15 metabolites by LC-MS.

Authors:  Kannan Rangiah; Wei-Ting Hwang; Clementina Mesaros; Anil Vachani; Ian A Blair
Journal:  Bioanalysis       Date:  2011-04       Impact factor: 2.681

7.  The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations.

Authors:  Yesha M Patel; Daniel O Stram; Lynne R Wilkens; Sung-Shim L Park; Brian E Henderson; Loic Le Marchand; Christopher A Haiman; Sharon E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-07       Impact factor: 4.254

8.  Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population.

Authors:  Taku Nagano; Makiko Shimizu; Kazuma Kiyotani; Tetsuya Kamataki; Ryohji Takano; Norie Murayama; Fumiaki Shono; Hiroshi Yamazaki
Journal:  Int J Environ Res Public Health       Date:  2010-07-20       Impact factor: 3.390

9.  Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling.

Authors:  Hiroshi Yamazaki; Kana Horiuchi; Ryohji Takano; Taku Nagano; Makiko Shimizu; Masato Kitajima; Norie Murayama; Fumiaki Shono
Journal:  Int J Environ Res Public Health       Date:  2010-09-01       Impact factor: 3.390

10.  Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.

Authors:  A Joseph Bloom; Sharon E Murphy; Maribel Martinez; Linda B von Weymarn; Laura J Bierut; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.